Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
DHR
Danaher Corp.
|
$6B | $1.72 | 3.79% | 43.39% | $258.09 |
|
CTSO
CytoSorbents Corp.
|
$10M | -$0.07 | 51.05% | -41.38% | $4.92 |
|
DCTH
Delcath Systems, Inc.
|
$25.3M | -$0.09 | 32.37% | -69.37% | $22.31 |
|
DGX
Quest Diagnostics, Inc.
|
$2.7B | $2.50 | 5.05% | 21.08% | $198.06 |
|
LH
Labcorp Holdings, Inc.
|
$3.6B | $4.14 | 6.94% | 131.26% | $299.71 |
|
STRR
Star Operating Cos., Inc.
|
$16.8M | -$0.76 | 50.04% | -65.48% | $12.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
DHR
Danaher Corp.
|
$231.47 | $258.09 | $163.5B | 47.64x | $0.32 | 0.53% | 6.87x |
|
CTSO
CytoSorbents Corp.
|
$0.69 | $4.92 | $43.3M | -- | $0.00 | 0% | 1.23x |
|
DCTH
Delcath Systems, Inc.
|
$10.32 | $22.31 | $364.4M | 1,186.21x | $0.00 | 0% | 4.92x |
|
DGX
Quest Diagnostics, Inc.
|
$175.92 | $198.06 | $19.6B | 20.64x | $0.80 | 1.79% | 1.83x |
|
LH
Labcorp Holdings, Inc.
|
$253.15 | $299.71 | $21B | 24.86x | $0.72 | 1.14% | 1.55x |
|
STRR
Star Operating Cos., Inc.
|
$10.90 | $12.00 | $37.5M | 0.75x | $0.00 | 0% | 0.52x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
DHR
Danaher Corp.
|
26.23% | 0.261 | 12.96% | 0.85x |
|
CTSO
CytoSorbents Corp.
|
75.25% | 1.075 | 46.74% | 1.49x |
|
DCTH
Delcath Systems, Inc.
|
0.83% | 1.825 | 0.25% | 12.82x |
|
DGX
Quest Diagnostics, Inc.
|
46.79% | 0.203 | 30.05% | 0.90x |
|
LH
Labcorp Holdings, Inc.
|
42.88% | 0.863 | 27.39% | 1.10x |
|
STRR
Star Operating Cos., Inc.
|
26.85% | 8.871 | 70.75% | 0.76x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
DHR
Danaher Corp.
|
$3.6B | $1.3B | 5.07% | 6.87% | 20.73% | $1.4B |
|
CTSO
CytoSorbents Corp.
|
$6.7M | -$2.7M | -27.15% | -89.32% | -28.07% | -$2.5M |
|
DCTH
Delcath Systems, Inc.
|
$17.9M | -$388K | 1.56% | 1.59% | -1.89% | $4.3M |
|
DGX
Quest Diagnostics, Inc.
|
$911M | $420M | 7.41% | 14.33% | 14.92% | $419M |
|
LH
Labcorp Holdings, Inc.
|
$955.6M | $403.2M | 5.61% | 10.25% | 11.32% | $280.5M |
|
STRR
Star Operating Cos., Inc.
|
$5.6M | -$866K | -2.74% | -3.67% | -3.65% | -$2.4M |
CytoSorbents Corp. has a net margin of 15% compared to Danaher Corp.'s net margin of -33.42%. Danaher Corp.'s return on equity of 6.87% beat CytoSorbents Corp.'s return on equity of -89.32%.
| Company | Gross Margin | Earnings Per Share | Invested Capital |
|---|---|---|---|
|
DHR
Danaher Corp.
|
59.87% | $1.27 | $69.2B |
|
CTSO
CytoSorbents Corp.
|
70.28% | -$0.05 | $36.4M |
Danaher Corp. has a consensus price target of $258.09, signalling upside risk potential of 11.5%. On the other hand CytoSorbents Corp. has an analysts' consensus of $4.92 which suggests that it could grow by 613.18%. Given that CytoSorbents Corp. has higher upside potential than Danaher Corp., analysts believe CytoSorbents Corp. is more attractive than Danaher Corp..
| Company | Buy Ratings | Hold Ratings | Sell Ratings |
|---|---|---|---|
|
DHR
Danaher Corp.
|
18 | 3 | 0 |
|
CTSO
CytoSorbents Corp.
|
1 | 1 | 0 |
Danaher Corp. has a beta of 0.892, which suggesting that the stock is 10.801% less volatile than S&P 500. In comparison CytoSorbents Corp. has a beta of 1.285, suggesting its more volatile than the S&P 500 by 28.454%.
Danaher Corp. has a quarterly dividend of $0.32 per share corresponding to a yield of 0.53%. CytoSorbents Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Danaher Corp. pays 20.42% of its earnings as a dividend. CytoSorbents Corp. pays out -- of its earnings as a dividend. Danaher Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
Danaher Corp. quarterly revenues are $6.1B, which are larger than CytoSorbents Corp. quarterly revenues of $9.5M. Danaher Corp.'s net income of $908M is higher than CytoSorbents Corp.'s net income of -$3.2M. Notably, Danaher Corp.'s price-to-earnings ratio is 47.64x while CytoSorbents Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Danaher Corp. is 6.87x versus 1.23x for CytoSorbents Corp.. Usually stocks with elevated PS ratios are considered overvalued.
| Company | Price/Sales Ratio | Price/Earnings Ratio | Quarterly Revenue | Quarterly Net Income |
|---|---|---|---|---|
|
DHR
Danaher Corp.
|
6.87x | 47.64x | $6.1B | $908M |
|
CTSO
CytoSorbents Corp.
|
1.23x | -- | $9.5M | -$3.2M |
Delcath Systems, Inc. has a net margin of 15% compared to Danaher Corp.'s net margin of 4.04%. Danaher Corp.'s return on equity of 6.87% beat Delcath Systems, Inc.'s return on equity of 1.59%.
| Company | Gross Margin | Earnings Per Share | Invested Capital |
|---|---|---|---|
|
DHR
Danaher Corp.
|
59.87% | $1.27 | $69.2B |
|
DCTH
Delcath Systems, Inc.
|
87.24% | $0.02 | $115.8M |
Danaher Corp. has a consensus price target of $258.09, signalling upside risk potential of 11.5%. On the other hand Delcath Systems, Inc. has an analysts' consensus of $22.31 which suggests that it could grow by 116.13%. Given that Delcath Systems, Inc. has higher upside potential than Danaher Corp., analysts believe Delcath Systems, Inc. is more attractive than Danaher Corp..
| Company | Buy Ratings | Hold Ratings | Sell Ratings |
|---|---|---|---|
|
DHR
Danaher Corp.
|
18 | 3 | 0 |
|
DCTH
Delcath Systems, Inc.
|
5 | 0 | 0 |
Danaher Corp. has a beta of 0.892, which suggesting that the stock is 10.801% less volatile than S&P 500. In comparison Delcath Systems, Inc. has a beta of 0.410, suggesting its less volatile than the S&P 500 by 59.033%.
Danaher Corp. has a quarterly dividend of $0.32 per share corresponding to a yield of 0.53%. Delcath Systems, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Danaher Corp. pays 20.42% of its earnings as a dividend. Delcath Systems, Inc. pays out -- of its earnings as a dividend. Danaher Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
Danaher Corp. quarterly revenues are $6.1B, which are larger than Delcath Systems, Inc. quarterly revenues of $20.6M. Danaher Corp.'s net income of $908M is higher than Delcath Systems, Inc.'s net income of $830K. Notably, Danaher Corp.'s price-to-earnings ratio is 47.64x while Delcath Systems, Inc.'s PE ratio is 1,186.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Danaher Corp. is 6.87x versus 4.92x for Delcath Systems, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
| Company | Price/Sales Ratio | Price/Earnings Ratio | Quarterly Revenue | Quarterly Net Income |
|---|---|---|---|---|
|
DHR
Danaher Corp.
|
6.87x | 47.64x | $6.1B | $908M |
|
DCTH
Delcath Systems, Inc.
|
4.92x | 1,186.21x | $20.6M | $830K |
Quest Diagnostics, Inc. has a net margin of 15% compared to Danaher Corp.'s net margin of 9.13%. Danaher Corp.'s return on equity of 6.87% beat Quest Diagnostics, Inc.'s return on equity of 14.33%.
| Company | Gross Margin | Earnings Per Share | Invested Capital |
|---|---|---|---|
|
DHR
Danaher Corp.
|
59.87% | $1.27 | $69.2B |
|
DGX
Quest Diagnostics, Inc.
|
32.35% | $2.15 | $13.8B |
Danaher Corp. has a consensus price target of $258.09, signalling upside risk potential of 11.5%. On the other hand Quest Diagnostics, Inc. has an analysts' consensus of $198.06 which suggests that it could grow by 12.59%. Given that Quest Diagnostics, Inc. has higher upside potential than Danaher Corp., analysts believe Quest Diagnostics, Inc. is more attractive than Danaher Corp..
| Company | Buy Ratings | Hold Ratings | Sell Ratings |
|---|---|---|---|
|
DHR
Danaher Corp.
|
18 | 3 | 0 |
|
DGX
Quest Diagnostics, Inc.
|
7 | 10 | 0 |
Danaher Corp. has a beta of 0.892, which suggesting that the stock is 10.801% less volatile than S&P 500. In comparison Quest Diagnostics, Inc. has a beta of 0.618, suggesting its less volatile than the S&P 500 by 38.214%.
Danaher Corp. has a quarterly dividend of $0.32 per share corresponding to a yield of 0.53%. Quest Diagnostics, Inc. offers a yield of 1.79% to investors and pays a quarterly dividend of $0.80 per share. Danaher Corp. pays 20.42% of its earnings as a dividend. Quest Diagnostics, Inc. pays out 39.15% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
Danaher Corp. quarterly revenues are $6.1B, which are larger than Quest Diagnostics, Inc. quarterly revenues of $2.8B. Danaher Corp.'s net income of $908M is higher than Quest Diagnostics, Inc.'s net income of $257M. Notably, Danaher Corp.'s price-to-earnings ratio is 47.64x while Quest Diagnostics, Inc.'s PE ratio is 20.64x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Danaher Corp. is 6.87x versus 1.83x for Quest Diagnostics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
| Company | Price/Sales Ratio | Price/Earnings Ratio | Quarterly Revenue | Quarterly Net Income |
|---|---|---|---|---|
|
DHR
Danaher Corp.
|
6.87x | 47.64x | $6.1B | $908M |
|
DGX
Quest Diagnostics, Inc.
|
1.83x | 20.64x | $2.8B | $257M |
Labcorp Holdings, Inc. has a net margin of 15% compared to Danaher Corp.'s net margin of 7.34%. Danaher Corp.'s return on equity of 6.87% beat Labcorp Holdings, Inc.'s return on equity of 10.25%.
| Company | Gross Margin | Earnings Per Share | Invested Capital |
|---|---|---|---|
|
DHR
Danaher Corp.
|
59.87% | $1.27 | $69.2B |
|
LH
Labcorp Holdings, Inc.
|
26.82% | $3.12 | $15.2B |
Danaher Corp. has a consensus price target of $258.09, signalling upside risk potential of 11.5%. On the other hand Labcorp Holdings, Inc. has an analysts' consensus of $299.71 which suggests that it could grow by 18.39%. Given that Labcorp Holdings, Inc. has higher upside potential than Danaher Corp., analysts believe Labcorp Holdings, Inc. is more attractive than Danaher Corp..
| Company | Buy Ratings | Hold Ratings | Sell Ratings |
|---|---|---|---|
|
DHR
Danaher Corp.
|
18 | 3 | 0 |
|
LH
Labcorp Holdings, Inc.
|
12 | 5 | 0 |
Danaher Corp. has a beta of 0.892, which suggesting that the stock is 10.801% less volatile than S&P 500. In comparison Labcorp Holdings, Inc. has a beta of 0.989, suggesting its less volatile than the S&P 500 by 1.121%.
Danaher Corp. has a quarterly dividend of $0.32 per share corresponding to a yield of 0.53%. Labcorp Holdings, Inc. offers a yield of 1.14% to investors and pays a quarterly dividend of $0.72 per share. Danaher Corp. pays 20.42% of its earnings as a dividend. Labcorp Holdings, Inc. pays out 32.58% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
Danaher Corp. quarterly revenues are $6.1B, which are larger than Labcorp Holdings, Inc. quarterly revenues of $3.6B. Danaher Corp.'s net income of $908M is higher than Labcorp Holdings, Inc.'s net income of $261.5M. Notably, Danaher Corp.'s price-to-earnings ratio is 47.64x while Labcorp Holdings, Inc.'s PE ratio is 24.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Danaher Corp. is 6.87x versus 1.55x for Labcorp Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
| Company | Price/Sales Ratio | Price/Earnings Ratio | Quarterly Revenue | Quarterly Net Income |
|---|---|---|---|---|
|
DHR
Danaher Corp.
|
6.87x | 47.64x | $6.1B | $908M |
|
LH
Labcorp Holdings, Inc.
|
1.55x | 24.86x | $3.6B | $261.5M |
Star Operating Cos., Inc. has a net margin of 15% compared to Danaher Corp.'s net margin of 14.56%. Danaher Corp.'s return on equity of 6.87% beat Star Operating Cos., Inc.'s return on equity of -3.67%.
| Company | Gross Margin | Earnings Per Share | Invested Capital |
|---|---|---|---|
|
DHR
Danaher Corp.
|
59.87% | $1.27 | $69.2B |
|
STRR
Star Operating Cos., Inc.
|
23.43% | $0.86 | $85.6M |
Danaher Corp. has a consensus price target of $258.09, signalling upside risk potential of 11.5%. On the other hand Star Operating Cos., Inc. has an analysts' consensus of $12.00 which suggests that it could grow by 10.09%. Given that Danaher Corp. has higher upside potential than Star Operating Cos., Inc., analysts believe Danaher Corp. is more attractive than Star Operating Cos., Inc..
| Company | Buy Ratings | Hold Ratings | Sell Ratings |
|---|---|---|---|
|
DHR
Danaher Corp.
|
18 | 3 | 0 |
|
STRR
Star Operating Cos., Inc.
|
1 | 1 | 0 |
Danaher Corp. has a beta of 0.892, which suggesting that the stock is 10.801% less volatile than S&P 500. In comparison Star Operating Cos., Inc. has a beta of 2.714, suggesting its more volatile than the S&P 500 by 171.399%.
Danaher Corp. has a quarterly dividend of $0.32 per share corresponding to a yield of 0.53%. Star Operating Cos., Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Danaher Corp. pays 20.42% of its earnings as a dividend. Star Operating Cos., Inc. pays out 19.54% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
Danaher Corp. quarterly revenues are $6.1B, which are larger than Star Operating Cos., Inc. quarterly revenues of $23.7M. Danaher Corp.'s net income of $908M is higher than Star Operating Cos., Inc.'s net income of $3.5M. Notably, Danaher Corp.'s price-to-earnings ratio is 47.64x while Star Operating Cos., Inc.'s PE ratio is 0.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Danaher Corp. is 6.87x versus 0.52x for Star Operating Cos., Inc.. Usually stocks with elevated PS ratios are considered overvalued.
| Company | Price/Sales Ratio | Price/Earnings Ratio | Quarterly Revenue | Quarterly Net Income |
|---|---|---|---|---|
|
DHR
Danaher Corp.
|
6.87x | 47.64x | $6.1B | $908M |
|
STRR
Star Operating Cos., Inc.
|
0.52x | 0.75x | $23.7M | $3.5M |
Signup to receive the latest stock alerts
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Market Cap: $4.6T
P/E Ratio: 64x
Market Cap: $4T
P/E Ratio: 37x
Market Cap: $3.8T
P/E Ratio: 39x
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.